EFFECTIVITY AND SAFETY OF TACALCITOL IN PSORIASIS VULGARIS IN SPANISH PATIENTS

Mirada A1, Lecha M1, Barnés E2, López JS4
1Laboratorios Isdin, Barcelona, Spain; 2H. Clinic i Provincial de Barcelona, Barcelona, Spain; 3Pharma-Consult, Barcelona, Spain; 4Pharma-Consult, Barcelona, Spain

OBJECTIVES: To analyse the effectivity and safety of tacalcitol in real daily conditions. METHODS: An epidemiological, observational, prospective and multicenter study of a cohort of patients with mild to moderate Psoriasis vulgaris has been performed. Treatment with tacalcitol ointment (4mg/g) was prescribed. Anthropometric and demographic characteristics of patients were recorded in addition to percentage of affected area and previous and current treatments. A lesion was selected as target for evaluation, of symptoms (erythema, desquamation and thickness) by a scale from 0 (absent) to 4 (maximum intensity of symptom). At follow-up (30 and 60 days) symptomatology and appearance of adverse events were evaluated. Psoriasis Area Severity Index (PASI) was calculated. RESULTS: Eight hundred twenty-one patients with mild to moderate Psoriasis vulgaris, (45.67% were men and 45.33% were women, mean age 43.59 ± 15.48 years) were included. After 2 months of treatment, patients showed a decrease of mean percentage of affected area of 7.83 ± 12.3 (from 15.97% ± 16.02% to 8.14 ± 10.59%). PASI decreased from 10.11 ± 7.89 to 3.00 ± 3.79 (p < 0.01). Percentage of patients without symptoms increased up to 85.44% for erythema, 93.11% for desquamation and 96.16% for thickness. Six adverse events were reported (1% of sample). Seventy-eight percent of investigators and 80% of patients evaluated effectivity of treatment as satisfactory. CONCLUSIONS: Tacalcitol was effective in symptomatic treatment of psoriasis. Treatment achieved improvement on affected area and intensity of symptoms as well. Excellent tolerability of tacalcitol was corroborated by the low rate of adverse events reported.

SKIN DISORDERS—Cost Studies

ECONOMIC EVALUATION OF TACROLIMUS OINTMENT VERSUS CURRENT CARE IN MODERATE TO SEVERE ATOPIC DERMATITIS

Moeremans K1, Annemans L2
1HEDM, Meise, Belgium; 2Ghent University, HEDM, Meise, NA, Belgium

OBJECTIVES: Topical steroids are the corner-stone of current treatment for atopic dermatitis (AD), a chronic fluctuating inflammatory skin disease. However, steroids carry a risk of local and systemic side effects limiting their long term use and effectiveness. The objective was to assess the incremental cost-effectiveness ratio (ICER) of the new topical immunomodulator Tacrolimus in moderate to severe AD. Tacrolimus has shown significant clinical improvement, maintained with long term intermittent treatment up to four years. METHODS: A Markov model was developed in MS-Excel. Model health states represent severe, moderate, mild, and virtually cured AD as defined by the Eczema Area and Severity Index (EASI). Based on prevalence data, 82% start with moderate, 18% as defined by the Eczema Area and Severity Index (EASI). Based on prevalence data, 82% start with moderate, 18% severe AD. Tacrolimus has shown significant clinical improvement, maintained with long term intermittent treatment up to four years. METHODS: A Markov model was developed in MS-Excel. Model health states represent severe, moderate, mild, and virtually cured AD as defined by the Eczema Area and Severity Index (EASI). Based on prevalence data, 82% start with moderate, 18% severe AD. The model simulates monthly severity fluctuations. Transitions among health states were calculated from two 1-year observational trials (Tacrolimus n = 93, current care n = 120). Tacrolimus consumption was obtained from the clinical trial, other resource utilisation from a two-round Delphi consensus panel (n = 8). Unit costs from the Belgian health care payers perspective were applied. Effects are expressed in “disease controlled days”, defined as days with mild or virtually cured AD. The time horizon was from 1 (basecase) to 3 years.
RESULTS: By the end of the first year, Tacrolimus increases the number of ‘disease controlled days’ with 59 days at an IC of €60, implying an ICER of 1€/disease controlled day. Better ICERs are obtained in severe AD, when taking into account UV light therapy costs in the steroid arm, currently not reimbursed in Belgium. Due to the long term clinical improvement, the ICER decreases with treatment duration and Tacrolimus ointment is estimated to become cost-saving as from 2 years treatment duration. CONCLUSION: Tacrolimus is a cost-effective treatment for moderate to severe AD, providing potential savings to the health care system during long term maintenance treatment.

THE COST-UTILITY OF CALCIPOTRIOL/BETHAMETHASONE (DOVOBET) OINTMENT IN THE TREATMENT OF PSORIASIS VULGARIS IN THE UNITED KINGDOM

Noerregard J1, Lowson D2
1LEO Pharma, Ballerup, Denmark, Denmark; 2LEO Pharma, Princes Risborough, Buckinghamshire, United Kingdom

OBJECTIVES: To evaluate the cost and utility of calcipotriol/bethamethasone (Dovobet) compared to calcipotriol (Dovonex) in the treatment of psoriasis vulgaris. METHODS: A four-state Markov model was designed to estimate the cost and utilities associated with psoriasis treatment over a full year. The model consists of four mutually exclusive health states: Controlled psoriasis, and three states of uncontrolled psoriasis: Initial treatment, subsequent treatment, and no treatment. Various sources were used to estimate the parameters of the model, but the primary source for utility scores and transition probabilities was an international phase III trial, estimating efficacy and the quality of life for 737 patients randomised to one of four different treatment options. Among the treatment options were calcipotriol/bethamethasone (Dovobet) once daily and the currently most frequently prescribed topical antipsoriatic in the bethamethasone (Dovobet) once daily and the currently

RESULTS: By the end of the first year, Tacrolimus increases the number of ‘disease controlled days’ with 59 days at an IC of €60, implying an ICER of 1€/disease controlled day. Better ICERs are obtained in severe AD, when taking into account UV light therapy costs in the steroid arm, currently not reimbursed in Belgium. Due to the long term clinical improvement, the ICER decreases with treatment duration and Tacrolimus ointment is estimated to become cost-saving as from 2 years treatment duration. CONCLUSION: Tacrolimus is a cost-effective treatment for moderate to severe AD, providing potential savings to the health care system during long term maintenance treatment.

Atopic dermatitis is considered in modern society to be a disease leading to large expenses of the state, person and family. OBJECTIVE: Pharmacoeconomic analysis of family expenses and losses connected with child’s atopic dermatitis. METHODS: cost and expenses analysis of the disease was conducted with account of expenses on pharmacotherapy, hospital and ambulance treatment, disablement pensions, temporary disability of parents and evaluation of the disease influence on the standard of life of the child and the whole family. In 2000–2003 we have conducted polling of families with children having atopic dermatitis, analysis of ambulatory cards and case histories in Vladivostok Children’s Municipal Clinic Hospital. Also, life standard questionnaires were filled in. RESULTS: Family expenses on the child’s disease treatment in 2000 were €658.9 rubles ($111.5), in 2001—€1241.2 rubles ($379), in 2002—€13400 rubles ($446), which made from 9.6 to 13.4% of family annual income. The largest specific weight of expenses (36.1%) was shown by drugs purchase: in 2000—€2486.8 rubles ($112), in 2001—€4833.2 ($136), 2002—€437.4 rubles ($161). In 2000 atopic dermatitis caused hospitalization of the child in average in 1.54 ± 0.2 cases in a year, period of treatment 15.62 ± 1.02 days. In 2002 share of expenses on basis antiinflammatory therapy and consultations of allergist and dermatologist increased, while number of hospitalization cases reduced to 1.01 ± 0.1, duration of hospitalization reduced down to 10.37 ± 0.94 days per one child in average during a year. Atopic dermatitis detected decrease in life quality not only of the child but also of the family as a whole. CONCLUSIONS: Effective pharmacotherapy and observance of hypoallergic every day life regulations led to improvement of children life quality, reduced expenses on hospital assistance, temporary disability and disablement but increased the burden of family expenses on drugs.

TREATMENT OF PSORIASIS WITH CONVENTIONAL SYSTEMIC AGENTS IS ASSOCIATED WITH HIGH MEDICAL COSTS AND FREQUENT TREATMENT FAILURE

Feldman S1, Evans C2, Russell M3
1Wake Forest University School of Medicine, Winston-Salem, NC, USA; 2Mapi Values USA, Boston, MA, USA; 3Biogen, Inc, Cambridge, MA, USA

Atopic dermatitis is considered in modern society to be a disease leading to large expenses of the state, person and family. OBJECTIVE: Pharmacoeconomic analysis of family expenses and losses connected with child’s atopic dermatitis. METHODS: cost and expenses analysis of the disease was conducted with account of expenses on pharmacotherapy, hospital and ambulance treatment, disablement pensions, temporary disability of parents and evaluation of the disease influence on the standard of life of the child and the whole family. In 2000–2003 we have conducted polling of families with children having atopic dermatitis, analysis of ambulatory cards and case histories in Vladivostok Children’s Municipal Clinic Hospital. Also, life standard questionnaires were filled in. RESULTS: Family expenses on the child’s disease treatment in 2000 were €658.9 rubles ($111.5), in 2001—€1241.2 rubles ($379), in 2002—€13400 rubles ($446), which made from 9.6 to 13.4% of family annual income. The largest specific weight of expenses (36.1%) was shown by drugs purchase: in 2000—€2486.8 rubles ($112), in 2001—€4833.2 ($136), 2002—€4837.4 rubles ($161). In 2000 atopic dermatitis caused hospitalization of the child in average in 1.54 ± 0.2 cases in a year, period of treatment 15.62 ± 1.02 days. In 2002 share of expenses on basis antiinflammatory therapy and consultations of allergist and dermatologist increased, while number of hospitalization cases reduced to 1.01 ± 0.1, duration of hospitalization reduced down to 10.37 ± 0.94 days per one child in average during a year. Atopic dermatitis detected decrease in life quality not only of the child but also of the family as a whole. CONCLUSIONS: Effective pharmacotherapy and observance of hypoallergic every day life regulations led to improvement of children life quality, reduced expenses on hospital assistance, temporary disability and disablement but increased the burden of family expenses on drugs.